Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Closed
24 Jul, 20:00
NYSE NYSE
$
25. 35
-0.01
-0.04%
$
142.93B Market Cap
14.55 P/E Ratio
1.68% Div Yield
25,625,444 Volume
1.43 Eps
$ 25.36
Previous Close
Day Range
25.26 25.54
Year Range
20.92 31.54
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 3 days
Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent COVID vaccine demand through the roof.

247wallst | 1 month ago
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.

Zacks | 1 month ago
50% Off - 2 Dividend Gems With Huge Income And Growth Potential

50% Off - 2 Dividend Gems With Huge Income And Growth Potential

Investing capital means balancing risk, goals, and timing, especially when markets face uncertainty and shifting global dynamics. I focus on long-term value and income. I highlight two undervalued opportunities with strong dividends that have suffered recent setbacks but show solid growth potential in key sectors like real estate and healthcare. Both picks combine resilience and strategic advantages, offering attractive yields and upside for dividend investors seeking quality income in a complex market environment.

Seekingalpha | 1 month ago
Should Value Investors Buy Pfizer (PFE) Stock?

Should Value Investors Buy Pfizer (PFE) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 month ago
PFE or LLY: Which Is the Better Value Stock Right Now?

PFE or LLY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?

Zacks | 1 month ago
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds

PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

Zacks | 1 month ago
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks

Wall Street Analysts Love These Ultra-High Yield Dividend Stocks

Alexandros Michailidis / iStock Editorial via Getty Images Pfizer Pharmaceutical company Pfizer Inc.

247wallst | 1 month ago
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare

Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent cliffs, risking about $20 billion in annual revenue, and is unlikely to avoid revenue declines in the next few years. Management is responding with cost cuts, acquisitions, and licensing deals, but growth prospects remain limited and stability is a key concern.

Seekingalpha | 1 month ago
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?

Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?

PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.

Zacks | 1 month ago
Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Pfizer Inc. (PFE) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Pfizer Inc. (NYSE:PFE ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference.

Seekingalpha | 1 month ago
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 1 month ago
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends

Pfizer's R&D Optimization Delivers Great Results & Secure Dividends

PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.

Seekingalpha | 1 month ago
Loading...
Load More